End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).Bijal Shah, William G. Wierda, Olalekan O. Oluwole et al.|Journal of Clinical Oncology|2019Cited by 38